AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04863690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
Study NCT04863690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Coaching
Description: All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
Study NCT04863690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Coaching plus Human Coaching
Description: All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
Study NCT05363540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre-incisional parasternal intercostal block
Description: LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
Study NCT05363540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-incisional parasternal intercostal block
Description: LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
Study NCT05901103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block (SPSIPB)
Description: Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
Study NCT05929339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin
Study NCT06507670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings
Study NCT06507384 — intervention group
Intervention type: OTHER
Intervention: AI-Based Risk Assessment Model
Description: Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
Study NCT05484323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
Study NCT05484323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
Study NCT05484323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cookie containing 0 g spirulina
Description: Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
Study NCT05484323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cookie containing 2.5 g spirulina
Description: TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
Study NCT05715515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panbio™
Description: The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users
Study NCT04881747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study NCT04881747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.
Study NCT05077592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Povidone Iodine
Description: Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
Study NCT05028257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines
Description: Pursuit of vaccination in case of anaphylactic reaction
Study NCT06128915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaccine
Description: Vaccination against 20 serotypes of S. pneumoniae
Study NCT06237621 — intervention group
Intervention type: DEVICE
Intervention: SnapshotNIR imaging
Description: SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
Study NCT05862740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Debulking Surgery in advanced ovarian cancer
Description: Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
Study NCT05862740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparotomic Debulking Surgery in advanced ovarian cancer
Description: Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
Study NCT04718376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study NCT04902573 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
Study NCT05623111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumtoxin-A 100 UNIT Injection
Description: Perineural injection
Study NCT05623111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
Study NCT04878536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen drink
Description: Testing product
Study NCT04878536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blank
Description: Placebo drink
Study NCT05735756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram 20mg
Description: Citalopram 20mg once a day for 12 weeks
Study NCT05735756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 12 weeks
Study NCT05764915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-264 phosphate tablets
Description: RGT-264 phosphate tablets will be administered orally once daily (QD).
Study NCT05074212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Factorial Assignment
Description: At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
Study NCT06448819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patients received Crohn's disease exclusion diet or Mediterranean diet
Study NCT05085912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
Study NCT05085912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
Study NCT05085912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
Study NCT06116695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human treated dentin matrix
Description: human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
Study NCT06116695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mineral Tri-Oxide Aggregate
Description: mineral trioxide aggregate was used as control
Study NCT06421779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Description: Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
Study NCT04843696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)
Description: the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
Study NCT05372328 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
Study NCT05300906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized 2-week mobile wellbeing intervention
Description: For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages.
Study NCT05300906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-personalized 2-week mobile wellbeing intervention
Description: For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages.
Study NCT06478537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn.
Study NCT06478537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100mg, qd
Study NCT05259007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis solved in lactic acid solvent
Description: propolis given as a dietary supplement which was solved in a lactic acid solvent.
Study NCT05259007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment
Study NCT05259007 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment
Study NCT05259007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment
Study NCT05259007 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV saline 0.9%
Description: Physiological serum solution is given as a placebo
Study NCT05259007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lactic acid
Description: given to determine if the improvement of the symptoms are due to propolis or the solvent
Study NCT04962009 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
Description: Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
Study NCT05218473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prolonged ECG monitoring
Description: Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
Study NCT05218473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure group
Description: Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
Study NCT04903249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Exercise Promotion Intervention
Description: Participants are instructed to increase weekly time spent exercising to >90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period.
Study NCT05275530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active FIT Choice
Description: The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
Study NCT05275530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Colonoscopy Choice
Description: The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.